IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma[1].
References:
[1]. Degorce SL, et al. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors TargetingMyD88L265P Mutant Diffuse Large B Cell Lymphoma. J Med Chem. 2019 Nov 1.
















